VJET

SEC source: 0001209191-23-003033 · doc4.xml · derivative · entry 2

JENKINS DAVID A · CIK 0001279803 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 20.955

Underlying: Common Stock · 20,955 shares

Expires not disclosed

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F2 · kind: On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).

F1 · price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F3 · derivative.expiration_date: Series X Convertible Preferred Stock has no expiration date

F4 · ownership.nature: Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee.

SEC source: 0001209191-23-003033 · doc4.xml · derivative · entry 1

JENKINS DAVID A · CIK 0001279803 · Director · Executive Chairman of Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,569.936

Underlying: Common Stock · 2,569,936 shares

Expires not disclosed

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F2 · kind: On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).

F1 · price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F3 · derivative.expiration_date: Series X Convertible Preferred Stock has no expiration date

SEC source: 0001209191-23-003028 · doc4.xml · derivative · entry 1

Caruso James Joseph · CIK 0001397215 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9.711

Underlying: Common Stock · 9,711 shares

Expires not disclosed

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F2 · kind: On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).

F1 · price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F3 · derivative.expiration_date: Series X Convertible Preferred Stock has no expiration date.

SEC source: 0001654954-23-003617 · section16.xml · derivative · entry 4

Meline Susanne · CIK 0001731684 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 14.056

Underlying: Common Stock · 14,056 shares

Expires not disclosed

F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F4 · kind: On January 9, 2023, the Issuer, completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation ("Catheter"), pursuant to an Amended and Restated Agreement and Plan of Merger (the "Merger"). In connection with the Merger, each share of Catheter common stock previously outstanding held by the reporting person now represents a number of shares of Series X Convertible Preferred Stock equal to approximately 0.6697, divided by one thousand (1,000).

F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of Common Stock, each share of Series X Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.

F5 · derivative.expiration_date: Series X Convertible Preferred Stock has no expiration date.

SEC source: 0001654954-23-002940 · section16.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · CEO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,083

F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock awards. This is not an open market sale of securities.

F2 · balance_after: Reflects shares as a result of a reverse stock split.

SEC source: 0001209191-22-031621 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,680

F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock awards. This is not an open market sale of securities.

SEC source: 0001209191-22-031625 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,480

F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock awards. This is not an open market sale of securities.

SEC source: 0001209191-21-066775 · doc4.xml · nonDerivative · entry 2

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,041

F2 · kind: Shares sold to satisfy the tax withholding requirement upon vesting of restricted stock awards.

SEC source: 0001209191-21-066773 · doc4.xml · nonDerivative · entry 2

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,721

F2 · kind: Shares sold to satisfy the tax withholding requirement upon vesting of restricted stock awards.

SEC source: 0001209191-21-066775 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,725

F1 · kind: Represents forfeiture of shares underlying restricted stock award granted on November 17, 2020.

SEC source: 0001209191-21-066773 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,870

F1 · kind: Represents forfeiture of shares underlying restricted stock award granted on November 17, 2020.

SEC source: 0001209191-21-039050 · doc4.xml · nonDerivative · entry 1

ENQUIST WILLIAM R · CIK 0001659002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,766

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.

SEC source: 0001209191-21-039054 · doc4.xml · nonDerivative · entry 1

Stafslien Joan · CIK 0001467816 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,410

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.

SEC source: 0001209191-21-039052 · doc4.xml · nonDerivative · entry 1

Mejia Richard Jr · CIK 0001445578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,946

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.

SEC source: 0001209191-21-039047 · doc4.xml · nonDerivative · entry 1

COLOMBATTO MARTIN J · CIK 0001208236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,439

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.

SEC source: 0001209191-21-039056 · doc4.xml · nonDerivative · entry 1

Meline Susanne · CIK 0001731684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,808

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) June 4, 2022, or (ii) the day prior to the date of the Stockholder's Annual Meeting next following June 4, 2021, subject to the reporting person's continued service.

SEC source: 0001209191-21-035493 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,622

F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock awards. This is not an open market sale of securities.

SEC source: 0001209191-21-008326 · doc4.xml · nonDerivative · entry 1

Meline Susanne · CIK 0001731684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,808

F1 · shares: Reported shares are represented by restricted stock units ("RSUs"), and each RSU is the economic equivalent of one share of Ra Medical Systems, Inc. common stock. The RSUs shall vest annually over a four year period, beginning on January 31, 2021, so that the RSUs will be fully vested on January 31, 2025, subject to the reporting person's continued service through each such vesting date.

SEC source: 0001209191-21-002585 · doc4.xml · nonDerivative · entry 1

ENQUIST WILLIAM R · CIK 0001659002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,766

F1 · shares: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022.

SEC source: 0001209191-21-002582 · doc4.xml · nonDerivative · entry 1

Mejia Richard Jr · CIK 0001445578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,946

F1 · shares: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022.

SEC source: 0001209191-21-002576 · doc4.xml · nonDerivative · entry 1

Saad Mark E · CIK 0001295913 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

F1 · shares: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022.

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 132,562.

SEC source: 0001209191-21-002572 · doc4.xml · nonDerivative · entry 1

COLOMBATTO MARTIN J · CIK 0001208236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,439

F1 · shares: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022.

SEC source: 0001209191-20-060215 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,484

F1 · shares: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001209191-20-060224 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,838

F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock awards. This is not an open market sale of securities.

SEC source: 0001209191-20-060220 · doc4.xml · nonDerivative · entry 1

Kraws Jeffrey J · CIK 0001380918 · Co-President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,533

F1 · shares: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 128,006.

SEC source: 0001209191-20-060208 · doc4.xml · nonDerivative · entry 1

Horwood Daniel · CIK 0001756566 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,896

F1 · shares: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001209191-20-059505 · doc4.xml · nonDerivative · entry 1

Stafslien Joan · CIK 0001467816 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,410

F1 · price: Represents the weighted average share price of an aggregate total of 4,410 shares purchased in the price range of $5.54 to $5.80 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares held of record by the Thomas & Joan Stafslien Family B Trust dated 6/17/1997, for which the reporting person serves as trustee.

SEC source: 0001209191-20-059501 · doc4.xml · nonDerivative · entry 1

COLOMBATTO MARTIN J · CIK 0001208236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,439

F1 · price: Represents the weighted average share price of an aggregate total of 8,700 shares purchased in the price range of $5.64 to $5.7999 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 161,736.

SEC source: 0001209191-20-060058 · doc4.xml · nonDerivative · entry 1

ENQUIST WILLIAM R · CIK 0001659002 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,263

F1 · price: Represents the weighted average share price of an aggregate total of 5,263 shares purchased in the price range of $5.71 to $5.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares held of record by the Enquist Family Trust UAD 12/13/1990, for which the reporting person serves as trustee.

SEC source: 0001209191-20-060051 · doc4.xml · nonDerivative · entry 1

Mejia Richard Jr · CIK 0001445578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,523

F1 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons indirect ownership being reduced by 180,562.

SEC source: 0001209191-20-059388 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,284

F1 · shares: The reported shares were issued as a restricted stock award ("RSA"). 50% of the shares underlying the RSA shall vest and become non-forfeitable as follows: 1/3 of the number of shares will vest on November 20, 2021, and 1/6th of the number of shares will vest on each May 20 and November 20 thereafter, such that 50% of the RSA will be fully vested on November 20, 2023; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. The remaining 50% of the shares underlying the RSA shall vest and become non-forfeitable upon certain performance milestones being met by November 20, 2021. Vesting in all instances is subject to the reporting person's continuous status as a Service Provider (as defined in the 2018 Equity Incentive Plan) through each vesting date.

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 48,194.

SEC source: 0001209191-20-059394 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,054

F1 · shares: The reported shares were issued as a restricted stock award ("RSA"). 50% of the shares underlying the RSA shall vest and become non-forfeitable as follows: 1/3 of the number of shares will vest on November 20, 2021, and 1/6th of the number of shares will vest on each May 20 and November 20 thereafter, such that 50% of the RSA will be fully vested on November 20, 2023; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. The remaining 50% of the shares underlying the RSA shall vest and become non-forfeitable upon certain performance milestones being met by November 20, 2021. Vesting in all instances is subject to the reporting person's continuous status as a Service Provider (as defined in the 2018 Equity Incentive Plan) through each vesting date.

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 139,200.

SEC source: 0001209191-20-059382 · doc4.xml · nonDerivative · entry 1

Horwood Daniel · CIK 0001756566 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,696

F1 · shares: The reported shares were issued as a restricted stock award ("RSA"). 50% of the shares underlying the RSA shall vest and become non-forfeitable as follows: 1/3 of the number of shares will vest on November 20, 2021, and 1/6th of the number of shares will vest on each May 20 and November 20 thereafter, such that 50% of the RSA will be fully vested on November 20, 2023; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. The remaining 50% of the shares underlying the RSA shall vest and become non-forfeitable upon certain performance milestones being met by November 20, 2021. Vesting in all instances is subject to the reporting person's continuous status as a Service Provider (as defined in the 2018 Equity Incentive Plan) through each vesting date.

F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 50,536.

SEC source: 0001209191-20-054812 · doc4.xml · nonDerivative · entry 1

ENQUIST WILLIAM R · CIK 0001659002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,085

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service.

SEC source: 0001209191-20-054824 · doc4.xml · nonDerivative · entry 1

Stafslien Joan · CIK 0001467816 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service.

SEC source: 0001209191-20-054816 · doc4.xml · nonDerivative · entry 1

Mejia Richard Jr · CIK 0001445578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,085

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service.

SEC source: 0001209191-20-054820 · doc4.xml · nonDerivative · entry 1

Saad Mark E · CIK 0001295913 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,085

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service.

SEC source: 0001209191-20-054817 · doc4.xml · nonDerivative · entry 1

COLOMBATTO MARTIN J · CIK 0001208236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,475

F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service.

SEC source: 0001209191-20-045187 · doc4.xml · derivative · entry 2

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-04

SEC source: 0001209191-20-045187 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,202

SEC source: 0001209191-20-045203 · doc4.xml · derivative · entry 2

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-04

SEC source: 0001209191-20-045203 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

SEC source: 0001209191-20-045195 · doc4.xml · derivative · entry 2

Kraws Jeffrey J · CIK 0001380918 · Co-President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-04

SEC source: 0001209191-20-045195 · doc4.xml · nonDerivative · entry 1

Kraws Jeffrey J · CIK 0001380918 · Co-President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,339

SEC source: 0001209191-20-045181 · doc4.xml · derivative · entry 2

Horwood Daniel · CIK 0001756566 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-04

SEC source: 0001209191-20-045181 · doc4.xml · nonDerivative · entry 1

Horwood Daniel · CIK 0001756566 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,641

SEC source: 0001209191-20-036747 · doc4.xml · nonDerivative · entry 1

Mejia Richard Jr · CIK 0001445578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,085

F1 · price: Represents the weighted share price of an aggregate total of 50,000 shares sold in the price range of $0.591 to $0.600 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-033288 · doc4.xml · nonDerivative · entry 1

ENQUIST WILLIAM R · CIK 0001659002 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,085

SEC source: 0001209191-20-032336 · doc4.xml · nonDerivative · entry 1

Jackson Andrew C. · CIK 0001636738 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,202

SEC source: 0001209191-20-032343 · doc4.xml · nonDerivative · entry 1

McGuire Jonathan Will · CIK 0001345539 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000